RaySearch Laboratories (Q2 Review): H2 needs to deliver
Q2 was weak, as already known from the July profit warning, mainly due to several larger US orders being delayed. With the first delayed orders...
92 Views
RaySearch Laboratories (Q2 Initial take): Confidence in a strong H2
RaySearch’s Q2 figures were largely known following the July profit warning. More importantly, management reiterates its full-year EBIT margin...
84 Views
RaySearch: Burden of proof now on H2
Today's profit warning is disappointing, but we view it as a timing issue rather than weaker underlying demand. Still, we expect the share to...
87 Views
Primer: Raysearch Laboratories AB (RAYB SS) - May 2026
RaySearch is a market leader in specialized radiation therapy software, with a near-monopolistic position in the high-growth proton therapy...
109 Views
RaySearch Laboratories (Q1 Initial take): Softer than expected but comforting updated financial target
RaySearch came in softer than we expected on sales and EBIT (but in line with consensus EBIT). The updated financial targets should mitigate a...
93 Views